China Independent Clinical Laboratory Industry Report, 2017-2021
  • Aug.2017
  • Hard Copy
  • USD $2,700
  • Pages:135
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZLC053
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900
      

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States and Japan. Furthermore, Chinese independent clinical laboratories can provide more than 2,000 test items, while the counterparts in the United States can offer over 4,000 test items.

However, China's independent clinical laboratory industry is progressing rapidly, presenting the CAGR of 41.4% during 2010-2016, with the market size reaching RMB9.6 billion (an upsurge of 37.1% year on year) in 2016.

Pushed by the promotion of hierarchical medical system and other favorable policies, the growth of the outsourcing demand from public and private hospitals under the pressure of cost control, the acceleration of population aging as well as the people's ever growing awareness of health, etc., the independent clinical laboratory market size in China will maintain growth rate of at least 30% in the next five years and reach RMB41.4 billion by 2021.

As of the end of 2016, there had been 468 independent clinical laboratories in China, an increase of 112 ones over the same period of last year. They were mainly distributed in the developed coastal areas, about 50% of which were located in Shanghai, Beijing, Guangdong, Zhejiang and Jiangsu.

At present, major independent clinical laboratory companies in China include KingMed Diagnostics, ADICON, DIAN Diagnostics, DAAN Gene, Shanghai Labway Clinical Laboraory, MedicalSystem Biotechnology, Beijing Lepu Gene Technology and so forth. With cutting-edge advantages in the number of laboratories and inspection items which directly demonstrate the competitiveness of enterprises, KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene held a combined market share of over 70% in 2016. In the future, leading enterprises will continue to accelerate the chain-based expansion of laboratory network nationwide, further enhance their competitiveness, and intensify the market concentration.

icl_副本.png

China Independent Clinical Laboratory Industry Report, 2017-2021 highlights the following:
20120114.gifOverview of China’s independent clinical laboratory industry, covering policy, international environment, status quo, market size, competitive landscape and development trend;
20120114.gifUpstream and downstream sectors of China’s independent clinical laboratory industry;
20120114.gifOperation, revenue structure, gross margin and independent clinical laboratory business of 20 companies in China.

1. Overview of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain

2. Overview of China Independent Clinical Laboratory Industry
2.1 Policy Environment
2.1.1 Access Policy
2.1.2 Industry Policy
2.2 International Environment
2.2.1 Status Quo
2.2.2 Benchmarking Enterprises
2.3 Status Quo
2.4 Market size
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 The Industry's Growth Rate Will Be Above 30% in the Next Five Years
2.6.2 Hierarchical Medical System Will Boost the Rapid Development of the Industry
2.6.3 The Laboratory Outsourcing Proportion of Public Hospitals Will Rise due to Cost Control
2.6.4 High-end Test Items Will Make More Revenue Contribution
2.6.5 The Rapid Development of Private Hospitals Will Stimulate the Demand in the Independent Clinical Laboratory Market
2.6.6 Independent Clinical Laboratory Institutions Will Become Technical Leaders amid Quick Technological Upgrades
2.6.7 The Aging Population Balloons and the Demand for Medical Laboratory Will Soar
2.6.8 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry

3. Upstream and Downstream Sectors of China Independent Clinical Laboratory Industry
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Competitive Landscape 
3.2 Downstream Sector
3.2.1 Quantity
3.2.2 Medical Services
3.2.3 Revenue
3.2.4 Health Costs

4. Key Players
4.1 KingMed Diagnostics
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Major Customers 
4.1.7 Independent Clinical Laboratory Business 
4.1.8 Forecast and Outlook
4.2 DIAN Diagnostics 
4.2.1 Profile
4.2.2 Operation 
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Independent Clinical Laboratory Business 
4.2.7 Forecast and Outlook
4.3 Shanghai Labway Clinical Laboratory 
4.3.1 Profile
4.3.2 Operation 
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Independent Clinical Laboratory Business 
4.3.7 Forecast and Outlook
4.4 DAAN Gene 
4.4.1 Profile
4.4.2 Operation 
4.4.3 Revenue Structure
4.4.4 R&D and Investment
4.4.5 Major Customers 
4.4.6 Independent Clinical Laboratory Business 
4.4.7 Forecast and Outlook
4.5 ADICON Clinical Laboratories
4.5.1 Profile
4.5.2 Independent Clinical Laboratory Business 
4.5.3 Developments
4.6 NYMPHAVN Biotechnology 
4.6.1 Profile
4.6.2 Operation 
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Independent Clinical Laboratory Business 
4.6.7 Forecast and Outlook
4.7 SurExam Biotechnology
4.7.1 Profile
4.7.2 Operation 
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D and Investment
4.7.6 Independent Clinical Laboratory Business 
4.7.7 Forecast and Outlook
4.8 MedicalSystem Biotechnology 
4.8.1 Profile
4.8.2 Operation 
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Independent Clinical Laboratory Business 
4.8.7 Forecast and Outlook
4.9 Beijing Lawke Health Laboratory
4.9.1 Profile
4.9.2 Operation 
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R&D and Investment
4.9.6 Forecast and Outlook
4.10 Beijing Lepu Gene Technology 
4.10.1 Profile
4.10.2 Operation 
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 R&D and Investment
4.10.6 Major Customers 
4.10.7 Forecast and Outlook
4.11 Shanghai Biotecan Pharmaceuticals
4.11.1 Profile
4.11.2 Operation 
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Independent Clinical Laboratory Business 
4.11.6 Forecast and Outlook
4.12 Jiangsu Superbio Life Science
4.12.1 Profile
4.12.2 Operation 
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Forecast and Outlook
4.13 Amoy Diagnostics
4.13.1 Profile
4.13.2 Operation 
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Independent Clinical Laboratory Business 
4.13.6 Forecast and Outlook
4.14 Guangdong Hybribio Biotech 
4.14.1 Profile
4.14.2 Operation 
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Independent Clinical Laboratory Business 
4.14.6 Forecast and Outlook
4.15 Other Enterprises
4.15.1 Kindstar Global
4.15.2 CapitalBio Corporation
4.15.3 Beijing Adinovo Gene Technology Co., Ltd.
4.15.4 Deyi Diagnostics
4.15.5 IPE Center for Clinical Laboratory
4.15.6 Centre Testing International Group Co., Ltd. (CTI)
Independent Clinical Laboratory Industry Chain
Comparison of Independent Clinical Laboratory Undertakers between China and USA
Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2017
Development History of U.S. Independent Clinical Laboratory Industry
U.S. Independent Clinical Laboratory Market Share by Test Item
U.S. Clinical Laboratory Market Share by Demand Side
Comparison of Independent Clinical Laboratory Market Penetration among Europe, Americas and Japan, 2016 
Revenue and Net Income of Quest Diagnostics, 2009-2016
Revenue of Quest Diagnostics by Business, 2014-2016
Major M&As of Quest Diagnostics, 2006-2016
Revenue and Operating Income of LabCorp, 2010-2016
Revenue Breakdown of LabCorp by Business, 2013-2016
Major M&As of LabCorp, 2007-2017
Comparison of Independent Clinical Laboratory Market Penetration between China, and Europe, Americas and Japan, 2016
Comparison of Number of Diagnostic Items among Various Medical Institutions
Independent Clinical Laboratory Market Size in China, 2010-2016
Number of Independent Clinical Laboratories in China, 2010-2016
Independent Clinical Laboratory Revenue of Main Independent Clinical Laboratory Enterprises in China, 2014-2016
Marker Share of Independent Clinical Laboratory Enterprises in China, 2016
Comparison between Leading Independent Clinical Laboratory Companies in China, 2017
Independent Clinical Laboratory Market Size and YoY Growth in China, 2016-2021E
Policies Concerning Public Hospital Reform in China, 2015-2016
Number of Private Hospitals and YoY Growth in China, 2009-2017
Clinic Visits of Private Hospitals in China, 2012-2017
Population Aged over 60 in China, 2009-2021E
Classification of In Vitro Diagnosis
Development History of In Vitro Diagnosis Industry in China
In Vitro Diagnosis Market Size in China, 2009-2016
In Vitro Diagnosis Market Size in China, 2016-2021E
In Vitro Diagnosis Market Structure in China, 2016
Comparison of Diagnostic Instrument Varieties between Domestic and Foreign Enterprises
Competition Pattern of Diagnostic Reagent Industry in China
IVD Revenue and Market Share of Major Diagnostic Reagent Enterprises in China, 2014-2016
Number of Medical and Health Institutions in China, 2015-2017
Number of Hospitals in China, 2009-2017
Number of Hospitals in China by Economic Type, 2009-2017
Clinic Visits of Medical Institutions in China, 2015-2017
Clinic Visits of Hospitals in China, 2009-2017
Clinic Visits of Hospitals in China by Economic Type, 2012-2017 
Total Revenue of Medical and Health Institutions in China, 2010-2016
Total Revenue of Medical and Health Institutions in China, 2016-2021E
Total Revenue of Hospitals in China, 2009-2016
Total Revenue of Hospitals in China, 2016-2021E
Public Hospitals’ Inspection Revenue and % of Total Inspection Revenue in China, 2010-2016
Public Hospitals’ Inspection Revenue and % of Total Inspection Revenue in China, 2016-2021E
Inspection Revenue per Outpatient Visit and Inpatient Visit of Public Hospitals in China, 2010-2015 
Total Health Expenditure in China, 2010-2016
Total Health Expenditure in China, 2016-2021E
Revenue and Net Income of KingMed Diagnostics, 2014-2016
Revenue Breakdown of KingMed Diagnostics by Business, 2014-2016
Revenue Breakdown of KingMed Diagnostics by Region, 2014-2016
Gross Margin of KingMed Diagnostics, 2014-2016
Gross Margin of KingMed Diagnostics by Business, 2014-2016 
R&D Costs and % of Total Revenue of KingMed Diagnostics, 2014-2016
Fundraising Projects of KingMed Diagnostics by Initial Public Offerings
KingMed Diagnostics’ Revenue from Top 5 Clients and % in Total Revenue, 2014-2016
Independent Clinical Laboratory Subsidiaries of KingMed Diagnostics 
Laboratory Architecture of KingMed Diagnostics as of May 2017
Output, Capacity and Capacity Utilization of KingMed Diagnostics, 2014-2016
Unit Price of Main Services of KingMed Diagnostics, 2014-2016
Revenue and Net Income of KingMed Diagnostics, 2016-2021E
Revenue and Net Income of DIAN Diagnostics, 2013-2017
Revenue Breakdown of DIAN Diagnostics by Business, 2013-2016
Revenue Structure of DIAN Diagnostics by Business, 2013-2016
Revenue Breakdown of DIAN Diagnostics by Region, 2013-2016
Revenue Structure of DIAN Diagnostics by Region, 2013-2016
Gross Margin of DIAN Diagnostics by Business, 2013-2016
R&D Costs and % of Total Revenue of DIAN Diagnostics, 2013-2016
Independent Clinical Laboratory Subsidiaries of DIAN Diagnostics
DIAN Diagnostics’ Revenue from Independent Clinical Laboratory and % in Total Revenue, 2013-2016 
Revenue and Net Income of DIAN Diagnostics, 2016-2021E
Revenue and Net Income of Shanghai Labway Clinical Laboratory, 2013-2016
Operating Revenue Breakdown of Shanghai Labway Clinical Laboratory by Business, 2013-2016
Operating Revenue Structure of Shanghai Labway Clinical Laboratory by Business, 2013-2016
Gross Margin of Shanghai Labway Clinical Laboratory by Business, 2013-2016
R&D Costs and % of Total Revenue of Shanghai Labway Clinical Laboratory, 2013-2016
Independent Clinical Laboratory Subsidiaries of Shanghai Labway Clinical Laboratory
Main Diagnostic Items of Shanghai Labway Clinical Laboratory
Shanghai Labway Clinical Laboratory’s Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2016
Revenue and Net Income of Shanghai Labway Clinical Laboratory, 2016-2021E
Revenue and Net Income of Da An Gene, 2013-2017
Revenue Breakdown of Da An Gene by Product, 2013-2016
Revenue Structure of Da An Gene by Product, 2013-2016
Revenue Breakdown of Da An Gene by Region, 2013-2016
Revenue Structure of Da An Gene by Region, 2013-2016
R&D Costs and % of Total Revenue of Da An Gene, 2013-2016
Da An Gene’s Revenue from Top 5 Clients and % in Total Revenue, 2015-2016
Da An Gene’s Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2016
Independent Clinical Laboratory Subsidiaries of Da An Gene
Revenue and Net Income of Da An Gene, 2016-2021E
Independent Clinical Laboratory Subsidiaries of Adicon Clinical Laboratories
Revenue and Net Income of Nymphavn Biotechnology, 2013-2016
Revenue Breakdown of Nymphavn Biotechnology by Business, 2014-2016
Gross Margin of Nymphavn Biotechnology, 2013-2016
R&D Costs and % of Total Revenue of Nymphavn Biotechnology, 2013-2016
Nymphavn Biotechnology’s Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2016
Revenue and Net Income of Nymphavn Biotechnology, 2016-2021E
Subsidiaries and Main Businesses of SurExam Biotechnology
Revenue and Net Income of SurExam Biotechnology, 2013-2016
Operating Revenue Breakdown of SurExam Biotechnology by Business, 2013-2016
Operating Revenue Structure of SurExam Biotechnology by Business, 2013-2016
Gross Margin of SurExam Biotechnology, 2013-2016
R&D Costs and % of Total Revenue of SurExam Biotechnology, 2013-2016
SurExam Biotechnology’s Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2016
Revenue and Net Income of SurExam Biotechnology, 2016-2021E
Revenue and Net Income of Medicalsystem Biotechnology, 2013-2017
Revenue Breakdown of Medicalsystem Biotechnology by Business, 2013-2016
Revenue Structure of Medicalsystem Biotechnology by Business, 2013-2016
Gross Margin of Medicalsystem Biotechnology by Business, 2013-2016 
R&D Costs and % of Total Revenue of Medicalsystem Biotechnology, 2013-2016
Investment Progress of Fundraising Projects of Medicalsystem Biotechnology by the end of 2016
Medicalsystem Biotechnology’s Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2016
Financial Data of Main Independent Clinical Laboratory Subsidiaries of Medicalsystem Biotechnology, 2016
Newly-established Independent Clinical Laboratory Subsidiaries of Medicalsystem Biotechnology, 2016
Revenue and Net Income of Medicalsystem Biotechnology, 2016-2021E
Revenue and Net Income of Beijing Lawke Health Laboratory, 2013-2016
Revenue Breakdown of Beijing Lawke Health Laboratory by Region, 2014-2016
Gross Margin of Beijing Lawke Health Laboratory, 2013-2016
R&D Costs and % of Total Revenue of Beijing Lawke Health Laboratory, 2013-2016
Revenue and Net Income of Beijing Lawke Health Laboratory, 2016-2021E
Revenue and Net Income of Beijing Lepu Gene Technology, 2013-2016
Revenue Breakdown of Beijing Lepu Gene Technology by Business, 2014-2016
Gross Margin of Beijing Lepu Gene Technology, 2013-2016
R&D Costs and % of Total Revenue of Beijing Lepu Gene Technology, 2014-2016
Main R&D Projects of Beijing Lepu Gene Technology, 2016
Beijing Lepu Gene Technology’s Revenue from Top 5 Clients and % in Total Revenue, 2015-2016
Revenue and Net Income of Beijing Lepu Gene Technology, 2016-2021E
Revenue and Net Income of Shanghai Biotecan Pharmaceuticals, 2013-2016
Revenue Breakdown of Shanghai Biotecan Pharmaceuticals by Business, 2014-2016
Gross Margin of Shanghai Biotecan Pharmaceuticals, 2013-2016
Shanghai Biotecan Pharmaceuticals’ Revenue from Independent Clinical Laboratory and % of Total Revenue, 2014-2016
Revenue and Net Income of Shanghai Biotecan Pharmaceuticals, 2016-2021E
Subsidiaries of Jiangsu Superbio by the end of 2016
Revenue and Net Income of Jiangsu Superbio, 2014-2016
Revenue Breakdown of Jiangsu Superbio by Business, 2014-2016
Gross Margin of Jiangsu Superbio, 2014-2016
Revenue and Net Income of Jiangsu Superbio, 2016-2021E
Revenue and Net Income of Amoy Diagnostics, 2014-2016
Operating Revenue Breakdown of Amoy Diagnostics by Business, 2014-2016
Gross Margin of Amoy Diagnostics, 2014-2016
Gross Margin of Amoy Diagnostics by Business, 2014-2016
Amoy Diagnostics’ Revenue from Independent Clinical Laboratory and % of Total Revenue, 2014-2016
Revenue and Net Income of Amoy Diagnostics, 2016-2021E
Revenue and Net Income of Guangdong Hybribio Biotech, 2014-2016
Operating Revenue Breakdown of Guangdong Hybribio Biotech by Product, 2014-2016
Gross Margin of Guangdong Hybribio Biotech by Business, 2014-2016
Guangdong Hybribio Biotech’s Revenue from Independent Clinical Laboratory and % of Total Revenue, 2014-2016
Fundraising Projects of Guangdong Hybribio Biotech by Initial Public Offerings, 2017
Revenue and Net Income of Guangdong Hybribio Biotech, 2016-2021E
Milestones of Kindstar Global
Some Strategic Partners of ADINOVO

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统